Research graph
References from Associating Mycobacterium tuberculosis genomic variants with minimum inhibitory concentrations to delamanid and pretomanid. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2025 · External reference
Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging
10.1002/ddr.21498 · 2019 · External reference
Bedaquiline, Delamanid, Linezolid, and Clofazimine for treatment of pre-extensively drug-resistant tuberculosis
10.1093/cid/ciac528 · 2023 · External reference
Transmission as a key driver of resistance to the new tuberculosis drugs
10.1056/nejmc2404644 · 2025 · External reference
Delamanid or pretomanid? A Solomonic judgement!
10.1093/jac/dkab505 · 2022 · External reference
Unresolved reference
2019 · External reference
Unresolved reference
2020 · External reference
Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis
10.1128/aac.00308-15 · 2015 · External reference
Delamanid resistance: update and clinical management
10.1093/cid/ciaa755 · 2020 · External reference
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid
10.1093/jac/dkaa136 · 2020 · External reference
Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis
10.1128/aac.01948-20 · 2020 · External reference
Spontaneous mutational patterns and novel mutations for delamanid resistance in Mycobacterium tuberculosis
2022 · External reference
DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid
10.1038/s41467-023-39300-z · 2023 · External reference
Unresolved reference
2018 · External reference
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
10.1093/jac/dkac070 · 2022 · External reference
Treatment of highly drug-resistant pulmonary tuberculosis
10.1056/nejmoa1901814 · 2020 · External reference
Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice
10.1016/j.ijantimicag.2023.106953 · 2023 · External reference
Unresolved reference
2024 · External reference
More nuance and transparency are needed when setting breakpoints for antimicrobial susceptibility testing of pretomanid
10.1016/j.cmi.2024.12.035 · 2025 · External reference
Unresolved reference
2023 · External reference
Designing molecular diagnostics for current tuberculosis drug regimens
10.1080/22221751.2023.2178243 · 2023 · External reference
Resazurin microtiter assay plate: Simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis
10.1128/aac.46.8.2720-2722.2002 · 2002 · External reference
Metagenome analysis using the Kraken software suite
10.1038/s41596-022-00738-y · 2022 · External reference
IQ-TREE 2: New Models and efficient methods for phylogenetic inference in the genomic era
10.1093/molbev/msaa015 · 2020 · External reference
Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering
2020 · External reference
Unresolved reference
2021 · External reference
Advantages of updated WHO mutation catalog combined with existing whole-genome sequencing-based approaches for Mycobacterium tuberculosis resistance prediction
10.1186/s13073-025-01458-0 · 2025 · External reference
Prevalence and genetic basis of Mycobacterium tuberculosis resistance to pretomanid in China
10.1186/s12941-024-00697-0 · 2024 · External reference
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis
10.1007/s10096-019-03551-w · 2019 · External reference
Unresolved reference
2025 · External reference
In Vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China
10.1128/aac.00900-17 · 2017 · External reference
